Validation of the Hepatoma Arterial Embolization PrognosticScore in European and Asian Populations and Proposed Modification

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 6, 2015, Pages 1204-1208.e2

  Pinato, David J ^a   Arizumi, Tadaaki ^b   Allara, Elias ^c   Jang, Jeong Won ^d   Smirne, Carlo ^e   Kim, Young Woon ^d   Kudo, Masatoshi ^b   Pirisi, Mario ^e   Sharma, Rohini ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TURIN   (Italy)

^d The Catholic University of Korea   (South Korea)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

AUROC; Hepatic; Liver Cancer; Outcome; Therapy

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN;

ACCURACY; ADULT; AGED; ARTICLE; ASIA; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; EUROPE; FEMALE; FOLLOW UP; HEPATOMA ARTERIAL EMBOLIZATION PROGNOSTIC SCORE; HUMAN; HYPOALBUMINEMIA; ITALY; JAPAN; KOREA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR VOLUME; UNITED KINGDOM; VALIDATION PROCESS; VERY ELDERLY; ARTIFICIAL EMBOLIZATION; CARCINOMA, HEPATOCELLULAR; CLINICAL MEDICINE; CLINICAL TRIAL; LIVER; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOGRAPHY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ASIA; CARCINOMA, HEPATOCELLULAR; CLINICAL MEDICINE; EMBOLIZATION, THERAPEUTIC; EUROPE; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84930343246     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.11.037     Document Type: Article

References (9)

1. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
2. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
3. Kadalayil L., Benini R., Pallan L., et al. Asimple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013, 24:2565-2570.
4. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
5. Pinato D.J., Stebbing J., Ishizuka M., et al. Anovel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). JHepatol 2012, 57:1013-1020.
6. Hanley J.A. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 1989, 29:307-335.
7. Camma C., Di Marco V., Cabibbo G., et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008, 28:62-75.
8. Cabibbo G., Genco C., Di Marco V., et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther 2011, 34:196-204.
9. Sieghart W., Hucke F., Pinter M., et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013, 57:2261-2273.